NASDAQ:IRMD - Iradimed Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$26.54 -1.56 (-5.55 %)
(As of 02/18/2019 04:45 AM ET)
Previous Close$26.54
Today's Range$26.26 - $28.19
52-Week Range$12.51 - $38.78
Volume70,638 shs
Average Volume74,287 shs
Market Capitalization$290.19 million
P/E Ratio61.72
Dividend YieldN/A
Beta1.85
IRadimed Corporation develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets under the MRidium name; and MRI compatible patient vital signs monitoring system under the IRadimed name. The company also offers IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its MRI compatible products through direct sales force and independent distributors. IRadimed Corporation was incorporated in 1992 and is headquartered in Winter Springs, Florida.

Receive IRMD News and Ratings via Email

Sign-up to receive the latest news and ratings for IRMD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:IRMD
CUSIPN/A
Phone407-677-8022

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$30.44 million
Cash Flow$0.2103 per share
Book Value$3.12 per share

Profitability

Net Income$6.30 million

Miscellaneous

Employees83
Market Cap$290.19 million
OptionableNot Optionable

Iradimed (NASDAQ:IRMD) Frequently Asked Questions

What is Iradimed's stock symbol?

Iradimed trades on the NASDAQ under the ticker symbol "IRMD."

How will Iradimed's stock buyback program work?

Iradimed announced that its board has approved a stock repurchase plan on Sunday, June 4th 2017, which allows the company to repurchase $8,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to reacquire shares of its stock through open market purchases. Stock repurchase plans are generally a sign that the company's board of directors believes its shares are undervalued.

How were Iradimed's earnings last quarter?

Iradimed Corp (NASDAQ:IRMD) released its earnings results on Wednesday, February, 6th. The medical equipment provider reported $0.14 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.13 by $0.01. The medical equipment provider earned $8.34 million during the quarter, compared to the consensus estimate of $8.19 million. Iradimed had a net margin of 20.71% and a return on equity of 14.26%. View Iradimed's Earnings History.

When is Iradimed's next earnings date?

Iradimed is scheduled to release their next quarterly earnings announcement on Monday, April 29th 2019. View Earnings Estimates for Iradimed.

What guidance has Iradimed issued on next quarter's earnings?

Iradimed issued an update on its first quarter 2019 earnings guidance on Wednesday, February, 6th. The company provided earnings per share guidance of $0.12-0.13 for the period, compared to the Thomson Reuters consensus estimate of $0.15. The company issued revenue guidance of $8.3-8.5 million, compared to the consensus revenue estimate of $9.1 million.Iradimed also updated its guidance to EPS.

What price target have analysts set for IRMD?

1 brokers have issued 1-year price objectives for Iradimed's stock. Their forecasts range from $35.00 to $35.00. On average, they expect Iradimed's share price to reach $35.00 in the next twelve months. This suggests a possible upside of 31.9% from the stock's current price. View Analyst Price Targets for Iradimed.

What is the consensus analysts' recommendation for Iradimed?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iradimed in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Iradimed.

Has Iradimed been receiving favorable news coverage?

Media headlines about IRMD stock have trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Iradimed earned a news impact score of 1.4 on InfoTrie's scale. They also assigned media stories about the medical equipment provider a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days.

Who are some of Iradimed's key competitors?

Who are Iradimed's key executives?

Iradimed's management team includes the folowing people:
  • Mr. Roger E. Susi, Founder, Chairman, CEO & Pres (Age 66)
  • Mr. Christopher K. Scott, CFO & Sec. (Age 49)
  • Mr. John McCreery, Chief Operating Officer (Age 64)
  • Mr. Brent Johnson, Exec. VP of Worldwide Sales & Marketing (Age 60)
  • Mr. Louis Waldman, Controller (Age 64)

Who are Iradimed's major shareholders?

Iradimed's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (2.94%), Ranger Investment Management L.P. (1.74%), Mondrian Investment Partners LTD (1.13%), Navellier & Associates Inc (1.07%), Northern Trust Corp (0.65%) and Cavalier Investments LLC (0.44%). Company insiders that own Iradimed stock include Christopher K Scott, Francis X Casey, John K Mccreery, Louis S Waldman, Monty K Allen, Roger E Susi and Steven M Nardi. View Institutional Ownership Trends for Iradimed.

Which major investors are selling Iradimed stock?

IRMD stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Caxton Associates LP, Algert Global LLC, Macquarie Group Ltd., Timpani Capital Management LLC, O Shaughnessy Asset Management LLC, Advisor Group Inc. and Northern Trust Corp. Company insiders that have sold Iradimed company stock in the last year include Christopher K Scott, Francis X Casey, John K Mccreery, Louis S Waldman, Monty K Allen and Steven M Nardi. View Insider Buying and Selling for Iradimed.

Which major investors are buying Iradimed stock?

IRMD stock was purchased by a variety of institutional investors in the last quarter, including Navellier & Associates Inc, Acadian Asset Management LLC, Ranger Investment Management L.P., Cavalier Investments LLC, Dupont Capital Management Corp, Mondrian Investment Partners LTD, Bank of America Corp DE and Nkcfo LLC. View Insider Buying and Selling for Iradimed.

How do I buy shares of Iradimed?

Shares of IRMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Iradimed's stock price today?

One share of IRMD stock can currently be purchased for approximately $26.54.

How big of a company is Iradimed?

Iradimed has a market capitalization of $290.19 million and generates $30.44 million in revenue each year. The medical equipment provider earns $6.30 million in net income (profit) each year or $0.43 on an earnings per share basis. Iradimed employs 83 workers across the globe.

What is Iradimed's official website?

The official website for Iradimed is http://www.iradimed.com.

How can I contact Iradimed?

Iradimed's mailing address is 1025 Willa Springs Dr., Winter Springs FL, 32708. The medical equipment provider can be reached via phone at 407-677-8022 or via email at [email protected]


MarketBeat Community Rating for Iradimed (NASDAQ IRMD)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  181 (Vote Outperform)
Underperform Votes:  182 (Vote Underperform)
Total Votes:  363
MarketBeat's community ratings are surveys of what our community members think about Iradimed and other stocks. Vote "Outperform" if you believe IRMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IRMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel